reason report
bottom line share sold today reaction compani
first sale miss sinc first downward oper sale growth
guidanc sinc split given protract issu
medic deliveri nutrit -- account total
sale -- surpris investor concern go-
forward outlook beyond us follow-up
call ir believ medic deliveri turnaround
achiev solid execut given compani track record
execut -- specif first quarter post-spin --
inclin give benefit doubt fact turnaround
materi within next quarter due dilig
suggest chang market dynam perman vs
transient would chang thesi long-term sale growth
acceler stori take conserv
stanc sale growth believ re-bas
model deliv upsid now-low estim
share may rangebound near-term pend
guidanc -- like late januari -- recommend share
investor time horizon
reiter op pt next month believ
share trade -- previous
rang dcf valuat deriv base case upsid
scenario supplement price target arriv via ev/
ev/ ebitda analys estim price-to-earnings
perspect valuat impli multipl
ep estim repres modest multipl expans current
level pe ep line
large-cap med-tech group support consist beat rais
quarter estim continu move higher
achiev long-term intact sale estim move
lower reflect continu impact market dynam near-
to-mid-term lower sale estim beyond
larg reflect protract weak medic deliveri
nutrit believ issu resolv lvp
large-volum parenter larg born brunt
destock grow line market svp
small-volum parenter recaptur lost share custom
switch iv push suppli constrain ep
estim remain unchang y/i
respect expect drive margin expans off-set
growth headwind top-lin
medic suppli devic
pt deriv rang
dcf valuat deriv
base case upsid scenario
supplement ev/fcf ev/
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm ep includ stock compens expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target ten consecut
beat rais ep quarter sinc spin oper margin alreadi track ahead
manag current long-rang plan increasingli strong free cash flow gener
believ post-spin new turnaround stori still room signific upsid
believ increment margin upsid potenti alreadi price believ magnitud
sale growth reacceler potenti free cash flow gener still underappreci
level increasingli becom strong free cash flow gener stori free
cash flow target vs potenti upsid free
cash flow view increas financi flexibl invest busi
drive even faster sale growth acceler invest inorgan outsid opportun
supplement top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recent updat long-term growth margin
target believ margin expans stori alreadi least partli price
stock manag current guid oper margin
see room upsid margin ramp believ major
upsid alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade rang
dcf valuat deriv base case upsid scenario supplement ev/
ev/ebitda analys ev/ebitda perspect valuat right line
group includ ew
risk includ failur execut margin expans initi new product launch delay
possibl acquisit either dilut perceiv further baxter growth goal
could pressur stock
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item visibl alpha
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu leerink partner estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
baxter sale y/i
sale billion usd
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
revenu report
constant currenc
basi flat oper
revenu report
constant currenc basi
revenu report impli
constant currenc
flat sale growth report
basi constant
sale growth report
basi constant
currenc basi
report constant
margin expans
bp
constant currenc basi
report
margin expans
bp
report impli
mid-point
constant currenc basi
margin expans
bp
report impli
mid-point
constant currenc basi
margin expans
bp
oper cf
cap ex
oper cf
cap ex
oper cf
ex
oper cf
ex
digit constant
oper
high-single-digit growth
includ cyclo
digit constant
currenc basi
constant currenc
basi includ
recothrom
constant
basi
constant
oper
constant
cyclo clari
constant
currenc basi
recothrom
preveleak
constant
currenc basi
basi
constant
currenc basi
basi
constant
currenc basi
basi
constant
constant
oper cf
cap ex
increas ex fx
report impli
constant currenc basi
report impli
constant currenc basi
report
adjust impact
cyclophosphamid competit
impact product exit
constant currenc basi
adjust impact
cyclophosphamid competit
impact product exit
compani report leerink partner estim
oper cf
ex
oper cf
cap ex
oper cf
cap ex
increas ex fx
mid-singl digit
point-of-car solut pd
innov home periton dialysi pd solut system
improv patient access home dialysi new system
design produc steril pd solut use small water filtrat
devic would place patient home integr
sharesourc telehealth platform
hdx therapi enabl
hdx therapi extend rang molecul filter
blood dialysi result filtrat profil
close mimic natur kidney addit clearanc profil
hdx enabl theranova simpl perform
convent hemodialysi hd design work
hd machin allow clinic offer hdx therapi use exist
resourc elimin need special equip ad
clinic workflow requir hdf addit hdf
perform effect patient hdx therapi enabl
theranova crucial step bring benefit theranova
patient market
expect new product pipelin acceler growth
contribut busi
compani report leerink partner estim
final regulatori pathway fda on-
demand periton dialysi pd system drug-devic combo
expect start clinic trial
oct note market share leader
pd global even introduct poc pd
like grow market rate
octob begun enrol patient us
end
januari expect launch
first set use continu renal replac therapi
crrt sepsi manag protocol label expans
oxiri blood purif set add baxter multi-organ
therapi offer util prismaflex system
oxiri label expans take effect
countri europ well geographi
east africa began launch label expans
select market outsid
roll-out on-go
februari began limit launch
anticip full european launch later year
expect improv outcom convent
hemodialysi use particular dialyz get
better level clearanc certain molecul
latest technolog acut care therapi
new dialyz could chang game long-term term
hd expect provid uniqu advantag
amia integr sharesourc technolog allow
patient clinician commun back forth daili
may convert roughli patient
 expect acceler
also sharesourc technolog
compani report leerink partner estim
